|Bid||2.1000 x 800|
|Ask||3.0000 x 1000|
|Day's Range||2.1500 - 2.3900|
|52 Week Range||1.0300 - 5.2500|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other cost reduction actions on track to realize $80 to $90 million in annualized.
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date relating to the New Drug Application (NDA) for AV001, a sterile injectable product designed for use in the hospital setting, by three months to December 15, 2019. The NDA for AV001 was originally accepted in May 2019 under the FDA’s Priority Review program with a statutory six-month review. This three-month extension relates to recent submissions Avadel made in response to FDA requests for additional analytical information. The FDA determined that these submissions constitute a major amendment and will require additional time to review.
DUBLIN, Ireland, Aug. 01, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointments of Courtney.
DUBLIN, Ireland, July 29, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a.
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters at the 33rd Annual Meeting of the Associated Professional Sleep Societies being held in San Antonio, Texas, from June 8-12, 2019. “Our once-nightly controlled-release sodium oxybate demonstrated lower overall peak plasma concentrations (Cmax) and similar total exposures (AUC), compared to twice-nightly sodium oxybate in a head-to-head study,” said Jordan Dubow, MD, Chief Medical Officer of Avadel Pharmaceuticals.
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointment of Gregory J. Divis as Chief Executive Officer and member of the Board of Directors. “Since being named Interim CEO at the beginning of 2019, Greg has done an excellent job leading the Company through rapid restructuring while directing our focus toward the successful development of FT218, our novel once-nightly therapy for narcolepsy patients,” said Geoffrey Glass, Chairman of Avadel’s Board of Directors.
DUBLIN, Ireland, May 22, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 15, 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply...
The Dublin-based company said it had a loss of 35 cents per share. The specialty pharmaceutical company posted revenue of $16.4 million in the period. The company's shares closed at $1.20. A year ago, ...
REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow, M.D., appointed as Chief Medical Officer Noctiva™-related assets sold; all operational activities have.
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Avadel Pharmaceuticals Plc (NASDAQ: AVDL ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 8:30 AM ...
DUBLIN, Ireland, April 29, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a.
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it has appointed Jordan Dubow, M.D., as Chief Medical Officer. Dr. Dubow brings extensive experience leading clinical development programs in sleep and neurological disorders to Avadel, where he will lead the development of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. “Dr. Dubow’s experience in a wide range of neurological disorders, especially sleep, will be invaluable to Avadel as we continue advancing FT218 toward approval and commercialization,” said Geoff Glass, Chairman of Avadel Pharmaceuticals.
The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. For the year, the company reported a loss of $95.3 million, ...
DUBLIN, Ireland, March 15, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results.
Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, March 15, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. Avadel Pharmaceuticals plc (AVDL) is a branded specialty pharmaceutical company. Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase III clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
Avadel Pharmaceuticals plc (AVDL) provided clarification regarding the restructuring actions announced earlier today. The restructuring actions do not trigger a default or violate covenants related to the 4.50% Exchangeable Senior Notes due in 2023.
Avadel Pharmaceuticals plc (AVDL), today announced a corporate restructuring to assure the financial health required to maximize the value of FT218, currently in Phase III development for the treatment of excessive daytime sleepiness (EDS) and Cataplexy in patients suffering from Narcolepsy. Avadel expects to realize $70 to $75 million in cost reductions in 2019 as compared to 2018 as a result of the restructuring plan, driven primarily by exiting NOCTIVA™. “It is clear that FT218, an investigational, once-nightly formulation of sodium oxybate, is the Company’s most promising and commercially-attractive asset targeting a large orphan market with an estimated value of nearly $1.5 billion in 2018,” said Greg Divis, interim Chief Executive Officer of Avadel.